Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Lnp023
2. 1644670-37-0
3. Lnp-023
4. Iptacopan [inn]
5. Iptacopan [usan]
6. Nvp-lnp023-nx
7. Nvp-lnp023
8. 8e05t07z6w
9. 4-[(2s,4s)-4-ethoxy-1-[(5-methoxy-7-methyl-1h-indol-4-yl)methyl]piperidin-2-yl]benzoic Acid
10. 4-[(2~{s},4~{s})-4-ethoxy-1-[(5-methoxy-7-methyl-1~{h}-indol-4-yl)methyl]piperidin-2-yl]benzoic Acid
11. Benzoic Acid, 4-((2s,4s)-4-ethoxy-1-((5-methoxy-7-methyl-1h-indol-4-yl)methyl)-2-piperidinyl)-
12. Benzoic Acid, 4-[(2s,4s)-4-ethoxy-1-[(5-methoxy-7-methyl-1h-indol-4-yl)methyl]-2-piperidinyl]-
13. Iptacopan [who-dd]
14. Unii-8e05t07z6w
15. Chembl4594448
16. Schembl16400416
17. Gtpl10710
18. Us9682968, Example-26a
19. Bdbm160475
20. Ex-a5728
21. Who 11259
22. Zinc223246892
23. At30389
24. Compound 41 [pmid: 32073845]
25. Hy-127105
26. Cs-0093107
27. A935227
28. 4-((2s,4s)-(4-ethoxy-1-((5-methoxy-7-methyl-1h-indol-4-yl)methyl)piperidin-2-yl))benzoic Acid
29. 4-((2s,4s)-4-ethoxy-1-((5-methoxy-7-methyl-1h-indol-4-yl)methyl)piperidin-2-yl)benzoicacid
30. Jgq
| Molecular Weight | 422.5 g/mol |
|---|---|
| Molecular Formula | C25H30N2O4 |
| XLogP3 | 1.8 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 7 |
| Exact Mass | 422.22055744 g/mol |
| Monoisotopic Mass | 422.22055744 g/mol |
| Topological Polar Surface Area | 74.8 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 594 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
NDC API
NDC Package Code : 44139-0100
Start Marketing Date : 2023-12-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is approved for the treatment of patients with IgA nephropathy (IgAN).
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Nephrology Brand Name: Fabhalta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2024
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis Receives FDA Approval for Fabhalta, A Complement Inhibitor for IgAN
Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is approved for the treatment of patients with IgA nephropathy (IgAN).
Brand Name : Fabhalta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 08, 2024
Details:
Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients with IgA nephropathy (IgAN).
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Nephrology Brand Name: Fabhalta
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis Data Show Significant Proteinuria Reduction of 38.3% for IgA Nephropathy Patients
Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients with IgA nephropathy (IgAN).
Brand Name : Fabhalta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 15, 2024
Details:
Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Brand Name: Fabhalta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis' Fabhalta® (iptacopan) Gets Positive CHMP Opinion for PNH
Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia.
Brand Name : Fabhalta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 22, 2024
Details:
LNP023 (iptacopan), an oral, Factor B inhibitor of the alternative complement pathway being developed in Phase 3 for patients with C3 glomerulopathy, which met its primary endpoint by providing clinically meaningful and statistically significant proteinuria reduction.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Nephrology Brand Name: LNP023
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LNP023 (iptacopan), an oral, Factor B inhibitor of the alternative complement pathway being developed in Phase 3 for patients with C3 glomerulopathy, which met its primary endpoint by providing clinically meaningful and statistically significant proteinu...
Brand Name : LNP023
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2023
Details:
FDA approved Fabhalta® (iptacopan), a Factor B inhibitor of the alternative complement pathway 15-17, as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Brand Name: Fabhalta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis receives FDA Approval for Fabhalta® (iptacopan), offering Superior Hemoglobin Improvemen...
Details : FDA approved Fabhalta® (iptacopan), a Factor B inhibitor of the alternative complement pathway 15-17, as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Brand Name : Fabhalta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
Details:
LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysis in PNH.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Nephrology Brand Name: LNP023
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysi...
Brand Name : LNP023
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 02, 2023
Details:
LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysis in PNH.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Brand Name: LNP023
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysi...
Brand Name : LNP023
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 26, 2023
Details:
LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysis in PNH.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Brand Name: LNP023
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysi...
Brand Name : LNP023
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 13, 2022
Details:
LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysis in PNH.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Brand Name: LNP023
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysi...
Brand Name : LNP023
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 08, 2022
Details:
LNP023 (Iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysis in PNH.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Brand Name: LNP023
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LNP023 (Iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysis in...
Brand Name : LNP023
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Patents & EXCLUSIVITIES
US Patents
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]US Exclusivities
Exclusivity Code : NCE
Exclusivity Expiration Date : 2028-12-05
Application Number : 218276
Product Number : 1
Exclusivity Details :
Exclusivity Code : ODE-456
Exclusivity Expiration Date : 2030-12-05
Application Number : 218276
Product Number : 1
Exclusivity Details :
Exclusivity Code : I-949
Exclusivity Expiration Date : 2027-08-07
Application Number : 218276
Product Number : 1
Exclusivity Details :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
